Assetmark Inc. Purchases 7,621 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Assetmark Inc. lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Rating) by 52.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,174 shares of the medical equipment provider’s stock after purchasing an additional 7,621 shares during the quarter. Assetmark Inc.’s holdings in Zimmer Biomet were worth $2,318,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Creative Financial Designs Inc. ADV boosted its position in shares of Zimmer Biomet by 21.3% during the third quarter. Creative Financial Designs Inc. ADV now owns 563 shares of the medical equipment provider’s stock worth $59,000 after purchasing an additional 99 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Zimmer Biomet by 9.8% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 131,284 shares of the medical equipment provider’s stock worth $13,726,000 after purchasing an additional 11,759 shares in the last quarter. Pinnacle Associates Ltd. boosted its position in shares of Zimmer Biomet by 15.6% during the third quarter. Pinnacle Associates Ltd. now owns 5,277 shares of the medical equipment provider’s stock worth $552,000 after purchasing an additional 711 shares in the last quarter. Farmers & Merchants Investments Inc. boosted its position in shares of Zimmer Biomet by 5.8% during the third quarter. Farmers & Merchants Investments Inc. now owns 1,860 shares of the medical equipment provider’s stock worth $194,000 after purchasing an additional 102 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Zimmer Biomet by 267.6% during the third quarter. SG Americas Securities LLC now owns 58,702 shares of the medical equipment provider’s stock worth $6,137,000 after purchasing an additional 42,735 shares in the last quarter. 87.21% of the stock is owned by institutional investors.

Zimmer Biomet Trading Up 0.1 %

ZBH opened at $123.38 on Tuesday. Zimmer Biomet Holdings, Inc. has a twelve month low of $100.39 and a twelve month high of $135.05. The company has a quick ratio of 1.05, a current ratio of 1.98 and a debt-to-equity ratio of 0.41. The company has a fifty day moving average of $121.97 and a 200-day moving average of $113.89. The stock has a market cap of $25.89 billion, a PE ratio of 93.47, a price-to-earnings-growth ratio of 2.32 and a beta of 1.03.

Zimmer Biomet (NYSE:ZBHGet Rating) last posted its quarterly earnings data on Wednesday, November 2nd. The medical equipment provider reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.56 by $0.02. Zimmer Biomet had a net margin of 3.89% and a return on equity of 11.92%. The company had revenue of $1.67 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period in the prior year, the company posted $1.81 earnings per share. Zimmer Biomet’s revenue for the quarter was down 13.2% compared to the same quarter last year. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 6.84 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, January 31st. Shareholders of record on Tuesday, December 27th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date of this dividend is Friday, December 23rd. Zimmer Biomet’s payout ratio is 72.73%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ZBH shares. Piper Sandler lifted their price target on shares of Zimmer Biomet from $120.00 to $130.00 in a research report on Thursday, January 5th. StockNews.com began coverage on shares of Zimmer Biomet in a research report on Wednesday, October 12th. They set a “buy” rating on the stock. Barclays initiated coverage on shares of Zimmer Biomet in a research report on Monday, October 17th. They set an “underweight” rating and a $104.00 price target on the stock. Royal Bank of Canada upgraded shares of Zimmer Biomet from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $125.00 to $141.00 in a research note on Monday, January 9th. Finally, Morgan Stanley upped their price target on shares of Zimmer Biomet from $120.00 to $135.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $128.86.

Zimmer Biomet Profile

(Get Rating)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.

Featured Stories

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.